Farm supply stocks are at the top of the list, but they’re not the only ones.
The other categories are often more undervalued.
Farm production in Australia is often down in the first half of the year, and in the second, with the end of the summer, the value of agricultural products will often be down.
We’re also seeing an increasing number of commodity-based crops being shipped off the ground.
For some, it’s a good sign for the Australian economy that we’re beginning to get the farm price bubble, says Andrew Kiely, a commodity strategist with IHS Global Insight.
“But it will be a while before we see a significant rebound in commodity prices.”
The biggest problem for farmers is the high costs of growing and shipping food, and it will likely take some time for farmers to recover from that, he says.
“There’s a huge amount of uncertainty around what’s going to happen in the short to medium term.”
Experts at the UK’s largest drugmakers say they have developed a new tool that can clean and treat contaminated boots that are often left in a factory for months.
The Rydon Laboratories Advanced Boot Cleaner, or ADL, has been tested on patients in hospitals across the UK.
The company said the product had been in use in the UK for about five years and that it was the first to be used in the field.
Dr David Gwynne, chief executive of Rydons medical supply group, said: “We believe that this product is the most effective and most cost-effective treatment of contaminated footwear we have tested.”ADL is a patented device that can be applied to contaminated boots, as well as to contaminated shoes and shoeshoes, to treat any kind of contamination.
“The device has been used on patients for more than five years to treat and remove any potentially contaminated footwear from hospitals and retail shops across the country.”
The product works by using an aerosol spray, or sprayer, to penetrate the outer layers of a contaminated boot, to remove any solvents and other contaminants.
This allows it to be removed from the boots in a relatively short period of time, said Dr Gwynnes.
“It can be used for two or three hours, and then the boots can be removed in about 24 hours,” he added.
The ADL can also be used to treat contaminated footwear and shoes from the following categories: “Boots that are manufactured by industrial suppliers” and “Footwear that is manufactured in factories that are not part of a licensed manufacturing operation”.
Dr Gwynns said that, unlike the standard ADL device, the ADL was not expensive, had a high level of safety and was used in a safe and efficient manner.
He added: “It is a safe product that we believe is of great value to the public and it has a long history in the industry.”
Our approach to safety has been based on our understanding of how the shoe industry operates and how the human body reacts to solvent and other solvate substances.
“We believe ADL is safe and effective, and is a perfect fit for our manufacturing process.”
“We have a long-standing relationship with Rydonics and we are committed to working with them on further development of the ADl.”
He added that the ADLL would not be available to the general public until further orders had been placed, but that it would be available in pharmacies for around the same price as standard ADl products.
Dr Gynne added that Rydonic had been providing the ADLC for about a year, and that the company had received a large number of applications for the product.
“I believe that the initial trials have shown that it is safe,” he said.
“The results from the trials have been very encouraging, and we anticipate that we will have a large volume of ADL available in the next two to three weeks.”
The ADLC, which can be found on Rydos online store, has a three-stage process.
First, it is applied to the inside of the boots, which have to be cleaned and disinfected first, and secondly, to the soles, which are then treated with a cleaning solution.
The company said it has been testing ADL on patients since May and has found it to perform as well or better than standard ADs.
Dr Chris McLean, Rydones managing director, said that the technology had been tested extensively in both inpatient and outpatient settings, and was now being trialled in hospital settings.
He said:”Rydonics is very proud to be working with Rynons in developing ADL as a first-of-its-kind product, and its successful trials in patients suggest it will be widely available in pharmacy across the NHS in the coming months.”